Cetuximab and chemotherapy for patients with unresectable CRC liver metastasis: Are we changing the natural course of the disease?

Onkologie

Volumn 30, Issue 12, 2007, Pages 602-604

  Ramos, Francisco Javier ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADD ON THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE COURSE; EDITORIAL; HUMAN; LIVER METASTASIS; LIVER RESECTION; MONOTHERAPY; SURVIVAL RATE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 37049036592     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110799     Document Type: Editorial

References (23)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
2. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-827.
3. Imamura H, Seyama Y, Kokudo N, Aoki T, Sano K, Minagawa M, Sugawara Y, Makuuchi M: Single and multiple resections of multiple hepatic metastases of colorectal origin. Surgery 2004;135:508-517.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
5. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
6. Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Ruckle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Muller L, Genicot B, Anak O, Nordlinger B: Phase III study of weekly highdose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-4865.
7. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-520.
8. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Levi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-669.
9. Alberts SR, Donhoe JH, Mahoney MR, Horvath WL, Sternfeld WC, Dikhil SR, Levitt R, Rowland KM, Sargent DJ, Goldberg RM: Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. ASCO Meeting Abstracts 2003;22:1053.
10. Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005;16:425-429.
11. Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-1346.
12. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
13. Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with Cetuximab/FOLFOX-4 in the treatment of mCRC epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-456.
14. Rosenberg AH, Loehrer PJ, Needle MN, Waksal H, Hollywood E, Ramos L, Saltz LB: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). ASCO Meeting Abstracts 2002;21:536.
15. Peeters M, Raoul JL, van Laethem JL, Rougier P, Brezault C, Husseini F, Cals L, Zubel A, Vedovato JC: Cetuximab in combination with irinotecan/5- fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). European Journal of Cancer (Supplement) 2005;3:188.
16. Köehne C, Zaluski J, Chung Rong C, Makhson A, D'Haens G, Pinter T, Lim R, Ruff P, Rougier P, Van Cutsem E: Cetuximab plus FOLFIRI first-line in metastatic colorectal cancer (mCRC): the randomized phase III CRYSTAL trial. Ann Oncol (Supplement) 2007;18:21.
17. Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH, Kim H: Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastasis. Onkologie 2007;30: DOI: 10.1159/000109957.
18. Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Sastre J, Tortora G, Ciardiello F, Kisker O, de Gramont A: Cetuximab in Combination with FOLFOX-4 in First-Line Metastatic Colorectal Cancer: Preclinical and Phase II Clinical Results. J Clin Oncol 2007. (In press).
19. Dittrich C, Hoehler T, Lordick F, Seufferlein T, Riemann J, Woell E, Herman T, Arnold D, Olchowka, Schmoll H: A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (MCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Ann Oncol (Supplement) 2006;17:24.
20. Venook A, Niedzwiecki D, Hollis D, et al.: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol (Meeting Abstracts) 2006;24:3509.
21. Schuch G, Staroslawska E, Nowacki M, Mitashok I, Kuznetsova E, Cortes P, Giron C, Tarasova O, Zubel A, Shparyk Y: Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of mCRC: OPUS, a phase II study. Ann Oncol (Supplement) 2007;18:18.
22. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-1319.
23. Leonard GD, Brenner B, Kemeny NE: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:2038-2048.